Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Boehringer Ingelheim Discovered Novel SPEVIGO® for the Treatment of Psoriasis Flares

Boehringer Ingelheim discovered novel spesolimab (marketed as SPEVIGO®) for the prevention of flares in adolescents and adults with generalised pustular psoriasis (GPP).

Spesolimab, a novel humanised selective antibody, has emerged as a significant advancement in the treatment of generalised pustular psoriasis (GPP). By blocking the activation of the interleukin-36 receptor (IL-36R), a key signalling pathway implicated in the development of various autoinflammatory diseases, including GPP, spesolimab offers a targeted therapeutic approach.

Spesolimab represents a significant milestone as the first approved treatment for GPP flares that directly focuses on the IL-36 pathway.

Its unique mechanism of action is thoroughly evaluated in a robust clinical trial, employing statistical power and randomisation with a placebo-controlled design. This rigorous assessment has demonstrated efficacy and safety in the management of GPP flares.

Notably, it has gained regulatory approval in nearly 40 countries, including the United States, Japan, Mainland China, and the European Union, for the management of GPP flares in adults.

Generalised pustular psoriasis (GPP) flares can appear suddenly, escalate rapidly, and pose a potentially life-threatening situation if not addressed promptly. This unsettling reality leaves individuals affected by GPP feeling anxious and uncertain about their future.

U.S. FDA has granted breakthrough therapy designation for spesolimab.
 

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024